MA42641A1 - Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih - Google Patents
Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vihInfo
- Publication number
- MA42641A1 MA42641A1 MA42641A MA42641A MA42641A1 MA 42641 A1 MA42641 A1 MA 42641A1 MA 42641 A MA42641 A MA 42641A MA 42641 A MA42641 A MA 42641A MA 42641 A1 MA42641 A1 MA 42641A1
- Authority
- MA
- Morocco
- Prior art keywords
- trispecific
- binding proteins
- prevention
- treatment
- hiv infection
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 3
- 108091008324 binding proteins Proteins 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305211 | 2016-02-24 | ||
| PCT/US2016/058540 WO2017074878A1 (en) | 2015-10-25 | 2016-10-24 | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42641A1 true MA42641A1 (fr) | 2019-03-29 |
Family
ID=55588187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42641A MA42641A1 (fr) | 2016-02-24 | 2016-10-24 | Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20190054182A1 (es) |
| EP (2) | EP3819310A1 (es) |
| JP (3) | JP7169190B2 (es) |
| KR (1) | KR20180063336A (es) |
| CN (4) | CN109311966B (es) |
| AR (1) | AR106466A1 (es) |
| AU (2) | AU2016347058B2 (es) |
| BR (1) | BR112018008011A2 (es) |
| CA (1) | CA3002664A1 (es) |
| CL (1) | CL2018001065A1 (es) |
| CO (1) | CO2018005337A2 (es) |
| CR (1) | CR20180288A (es) |
| DO (1) | DOP2018000102A (es) |
| EA (1) | EA201891028A1 (es) |
| ES (1) | ES2894304T3 (es) |
| HK (1) | HK1253385A1 (es) |
| HR (1) | HRP20211528T1 (es) |
| HU (1) | HUE056608T2 (es) |
| IL (2) | IL301140A (es) |
| MA (1) | MA42641A1 (es) |
| MX (2) | MX2018005048A (es) |
| MY (1) | MY192278A (es) |
| PE (1) | PE20181167A1 (es) |
| PH (1) | PH12018500873A1 (es) |
| PL (1) | PL3365366T3 (es) |
| RS (1) | RS62437B1 (es) |
| SG (1) | SG11201803324VA (es) |
| SI (1) | SI3365366T1 (es) |
| TW (2) | TW202219064A (es) |
| UY (1) | UY36965A (es) |
| WO (1) | WO2017074878A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| US10519222B2 (en) * | 2014-02-28 | 2019-12-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region |
| PL3365366T3 (pl) | 2015-10-25 | 2022-01-31 | Sanofi | Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV |
| US11236152B2 (en) * | 2015-11-03 | 2022-02-01 | The United States of America, as represented by the Sectetary, Department of Health and Human Services | Neutralizing antibodies to HIV-1 GP41 and their use |
| RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| AR112257A1 (es) * | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| BR112020007002A2 (pt) * | 2017-10-10 | 2020-11-17 | Sanofi | anticorpos anti-cd38 e métodos de uso |
| CN111819196B (zh) * | 2017-12-21 | 2022-10-28 | 纽约市哥伦比亚大学理事会 | 双特异性hiv-1中和抗体 |
| BR112020013325A2 (pt) | 2018-01-12 | 2020-12-01 | Genzyme Corporation | métodos para quantificação de polipeptídeos |
| WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| BR112021006558A2 (pt) | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
| WO2020106713A1 (en) * | 2018-11-21 | 2020-05-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| JP2022527994A (ja) | 2019-04-09 | 2022-06-07 | サノフイ | 三重特異性結合性タンパク質、方法、およびその使用 |
| TW202104274A (zh) | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| IL292480A (en) | 2019-10-25 | 2022-06-01 | Sanofi Sa | Methods for the analysis of chain mispairs in multispecific binding proteins |
| WO2021203103A2 (en) * | 2020-04-03 | 2021-10-07 | Somasekar Seshagiri | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| AU2021333577A1 (en) * | 2020-08-25 | 2023-03-30 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
| AR128060A1 (es) * | 2021-12-21 | 2024-03-20 | Modex Therapeutics | Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| AU2002241922B2 (en) | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2009149189A2 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| EP2480572B1 (en) | 2009-09-25 | 2019-01-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
| CN103282385A (zh) | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
| BR112013029550A2 (pt) * | 2011-05-17 | 2022-04-19 | California Inst Of Techn | Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos |
| ES2749349T3 (es) * | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| WO2013070776A1 (en) | 2011-11-07 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing gp41 antibodies and their use |
| CN104271597B (zh) | 2011-12-08 | 2018-05-25 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP3401337A1 (en) * | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| US9951106B2 (en) | 2012-12-04 | 2018-04-24 | University Of Maryland, Baltimore | Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb |
| JP6898060B2 (ja) | 2012-12-13 | 2021-07-07 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｄｎａ抗体構築物およびその使用方法 |
| US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| DK2961771T3 (da) * | 2013-02-26 | 2020-03-02 | Roche Glycart Ag | Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA |
| AU2014227664A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Inc. | Dual specific binding proteins directed against TNFalpha |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| CN105873953A (zh) | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| US10961506B2 (en) | 2014-09-04 | 2021-03-30 | Stemcell Technologies Inc. | Soluble antibody complexes for T cell or NK cell activation and expansion |
| EP3247725B1 (en) | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| AU2016264753B2 (en) | 2015-05-20 | 2021-09-09 | Quantum-Si Incorporated | Method of determining the sequence of a nucleic acid using time resolved luminescence |
| US10654943B2 (en) | 2015-06-02 | 2020-05-19 | The Rockefeller University | Tri-specific antibodies for HIV therapy |
| BR112018005741A2 (pt) | 2015-09-22 | 2018-10-09 | Univ Pennsylvania | método de redirecionamento de células t para tratar infecção por hiv |
| PL3365366T3 (pl) | 2015-10-25 | 2022-01-31 | Sanofi | Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| LT3390441T (lt) | 2015-12-15 | 2021-11-10 | Gilead Sciences, Inc. | Žmogaus imunodeficito virusą neutralizuojantys antikūnai |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
| US20230242876A1 (en) | 2016-12-30 | 2023-08-03 | Shanghai Sinobio Biotech Co., Ltd. | Bifunctional molecule and use thereof |
| KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| US11845787B2 (en) | 2017-03-27 | 2023-12-19 | The Wistar Institute Of Anatomy And Biology | DNA antibody constructs for use against HIV |
| BR112020007002A2 (pt) | 2017-10-10 | 2020-11-17 | Sanofi | anticorpos anti-cd38 e métodos de uso |
| BR112021006558A2 (pt) | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 KR KR1020187014534A patent/KR20180063336A/ko active IP Right Grant
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en active Application Filing
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 BR BR112018008011A patent/BR112018008011A2/pt active Search and Examination
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
- 2018-10-04 HK HK18112682.8A patent/HK1253385A1/zh unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP2023085476A/ja active Pending
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42641A1 (fr) | Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih | |
| MA44670B1 (fr) | Protéines de liaison trispécifiques et/ou trivalentes | |
| WO2018050902A3 (en) | Multimers, tetramers & octamers | |
| PH12019500609A1 (en) | Cd123 binding proteins and related compositions and methods | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| WO2020136145A3 (en) | Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies | |
| MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
| MA54975B1 (fr) | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
| MY192090A (en) | Trispecific and/or trivalent binding proteins | |
| MX2022003911A (es) | Anticuerpo, composicion farmaceutica y metodo. | |
| MA54501A (fr) | Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer | |
| MA55609A (fr) | Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih | |
| MX2021003867A (es) | Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. | |
| MX2022006632A (es) | Anticuerpos ampliamente neutralizantes contra el vih. | |
| BR112021019915A2 (pt) | Proteínas de ligação triespecíficas, métodos e usos dos mesmos | |
| MX2018016413A (es) | Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina. | |
| EA202092229A1 (ru) | Мутеины cd4 и способы их применения | |
| TN2018000345A1 (en) | Trispecific and/or trivalent binding proteins | |
| WO2021118156A3 (ko) | 스위칭 결합제, 이의 제조 방법, 및 이를 이용한 약학 조성물, 검사 키트 및 항원과 항체의 분석 방법 | |
| MX2022016197A (es) | Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. | |
| WO2022212654A3 (en) | Cross-reactive monoclonal antibodies against coronaviruses | |
| EA202191187A1 (ru) | Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение | |
| BR112022011323A2 (pt) | Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos |